Cholangiocarcinoma in the Era of Precision Medicine
Open Access
- 5 April 2022
- journal article
- Published by IntechOpen in Digital Medicine and Healthcare Technology
- Vol. 2022, 1-3
- https://doi.org/10.5772/dmht.07
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.Journal of Clinical Oncology, 2022
- Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the FutureCurrent Oncology, 2022
- Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future PerspectivesCancer Genomics & Proteomics, 2020
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmCancers, 2020
- Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic informationScientific Reports, 2019
- Genomic spectra of biliary tract cancerNature Genetics, 2015